Background Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology
that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The …

Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid
biopsy-based testing has proven to be highly beneficial for identifying actionable cancer …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …

Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS
technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC …

Biomarker testing is crucial for treatment selection in advanced non-small cell lung cancer
(NSCLC). However, the quantity of available tissue often presents a key constraint for …

In recent years, personalized or precision medicine has made effective inroads into the
management of diseases, including respiratory diseases. The route to implementing this …

Summary Background The national Network Genomic Medicine (nNGM) Lung Cancer
provides comprehensive and high-quality multiplex molecular diagnostics and standardized …

One in three cancer deaths worldwide are caused by gastric and colorectal cancer
malignancies. Although the incidence and fatality rates differ significantly from country to …

The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing
to guide therapy choices. This article is the second of a two-part series. In Part 1, we …